Current Trials
ECHO Open to Acrrual Clinical Trials
Updated: 1/15/21
| Bladder / Urothelial Muscle Invasive Alliance A031701 A Phase II study of Dose-Dense Gemcitabine plus Cisplatin (DDGC) in patients with Muscle-Invasive Bladder Cancer with Bladder preservation for those patients whose tumors harbor deleterious DNA Damage Response (DDR) Gene alterations SGN22E-002 / EV-103 A Study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer SGN22E-003 / EV-302 An open-label, randomized, controlled phase 3 study of Enfortumab Vedotin in combination with Pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer. Colorectal Metastatic NRG-GI004 / SWOG-S1610 *Temperarily Closed* Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6 / Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer Lung ARRAY-818-202 A Phase II, Open-Label Study of Encorafenib + Binimetinib in Patients with BRAFv600E-Mutant Non-Small Cell Lung Cancer Alchemist Trials Adjuvant Trials for completely resected patients EGFR or ALK positive A151216 Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist) A081105 Randomized double blind Placebo controlled study of Erlotinib or Placebo in patients with completely resected Epidermal growth factor receptor (EGFR) mutant non-smallcell lung cancer (NSCLC) D910LC00001 MERMAID-1 A phase III, Randomized, Multicenter, Double-blind, Placebo-controlled study to determine the efficacy of Adjuvant Durvalumab in combination with Platinum-based Chemotherapy in completely Resected Stage II-III NSCLC (mermaid-1) E4512 A phase III double-blind trial for surgically resected early stage Non-Small Cell Lung cancer: Crizotinib versus Placebo for pateints with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein First Line Metastatic GSK 213400 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as maintenance Therapy in participants whose disease has remained stable or responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer (Zeal-1L) TAK-788-3001 A Randomized Phase 3 Multicenter Open-Label Study to compare the efficacy of TAK-788 as first-line treatment versus Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Second Line Metastatic Mirati MRT516-005 A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy Lymphoma D8227C00001 / ACE-LY-312 / Escalade A phase 3, Randomized, Double-Blind, Placebo-controlled study of Acalabrutinib in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects 65 years or younger with previously untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma Melanoma ECOG EA6134 Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma Prostate Cancer LAE201INT2101 A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone plus Afuresertib in Patients with Metastatic Castration-Resistant Prostate Cancer Following Standard of Care Treatment NRG-GU002 A Phase II-III trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel Rectal Cancer Neoadjuvant NRG-GI002 *Temporarily closed to Accrual* A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer Solid Tumors EAY131 Molecular Analysis for Therapy Choice (MATCH) check with Research to confirm which sub-groups are opened ML42439 /MYTACTIC An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors with Genomic Alterations or Protein Expression Patterns predictive of response SGNLVA-005 Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors Screening Lung Screening I-ELCAP International Early Lung Cancer Action Program: Enrollment and Screening Protocol Supportive Care Amgen Protocol 20170758 Neulasta Onpro *On Hold* A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with Non-Myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or other Physician Choice Options for Prophylaxis of FN CADEX-0001 – *On Hold* Development and Validation of a Multiplex qPCR Short Fragment Cell Free DNA Assay as a Potential Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer Ready 1 / CUSA-081-HEM-01 /YYA36723 *On Hold* Phase 3, Randomized, Double-Hem-Blind, Active and Placebo Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs) ES2018-01 Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors Seer – 020102 (SeerPro) A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers |
For more information on clinical trials, please contact: Dr. Susan Johnson, Director of Research sjohnson@echoct.com or 860-886-8362.